NEW YORK, March 1 (Reuters) - Amgen Inc. management moved on Thursday to reassure investors that the majority of use of its biggest product, the anemia drug Aranesp, will continue despite mounting ...

NEW YORK, April 19 (Reuters) - Amgen Inc.'s. anemia drug Aranesp showed no increased risk of death compared to a placebo in a study of small-cell lung cancer patients undergoing chemotherapy, sending ...

April 23, 2007 — Using actual US practice patterns and dosing, epoetin alfa (Epogen; peg-EPO therapy) effectively maintains hemoglobin (Hb) levels in hemodialysis patients, according to a presentation ...

After a stroke, uric acid therapy reduces disability in women. Epoetin dose is significantly associated with cardiovascular disease whether patients had lower or higher hemoglobin levels, study finds.

Amgen Inc.’s anemia treatment Aranesp is safe for use in kidney patients whose disease doesn’t require dialysis, a U.S. panel said Monday. Outside advisers to the Food and Drug Administration said the ...

Breast cancer patients (N = 354) receiving chemotherapy were randomly assigned in 1:1 ratio to epoetin alfa (40,000 U qw) or standard of care (SOC). QOL was assessed at baseline and week 12.

Early results from a novel treatment strategy for chemotherapy-related anemia: Epoetin alfa 60,000 U SC QW induction followed by 60,000 U SC Q2W Conclusions: Epoetin alfa was safe and well tolerated ...